Predicting early enables proactive interventions to help better inform decisions made in managing the patient’s pregnancy.
Sera Prognostics developed a biomarker signature for sPTB using proteomic technology. The PreTRM test is the first, and only clinically validated blood test to predict spontaneous preterm birth (sPTB) risk by measuring proteins that are over- or under-expressed and are predictive of premature birth (or delivery).
Sera’s PreTRM test is highly predictive of preterm delivery in asymptomatic, singleton pregnancies where blood is drawn at 19-20 weeks gestational age, with reported spontaneous preterm birth prediction Area Under the Curve (AUC) ranging between 0.75 and 0.93.5
Performed between 19 and 20 weeks of pregnancy
Reported as percentage indicating risk of delivering prematurely — before 37 weeks
PreTRM test results delivered within about two weeks of patient's blood draw from LabCorp
Sample Test Results
How the PreTRM Test is Processed
The PreTRM test is processed by Sera Prognostics, in partnership with LabCorp. With a nationwide network of patient service centers, patients can have their blood drawn in the 19th or 20th week of pregnancy at a local LabCorp patient service center, for testing at Sera Prognostics’ CLIA Laboratory (Clinical Laboratory Improvement Act), which performs high-complexity, proteomic testing.
The PreTRM test is performed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) to simultaneously measure multiple proteins in patients' blood. These proteins have been proven to be associated with spontaneous preterm birth.5 The concentrations of individual proteins are then combined to establish a PreTRM test result that represents an individual woman’s risk of spontaneous preterm delivery for her current pregnancy. Results are sent to the patient's health care provider within about 2 weeks of her blood draw.